Though it contrasted with accepted scientific practice, “[t]he focus on intellectual property was thus developed as a prominent business strategy for securing the infusion of venture capital at early stages of research and development,” writes Doogab Yi in his book The Recombinant University: Genetic Engineering and the Emergence of Stanford Biotechnology.20 Stanford pulled in over a quarter of a billion dollars in commercial royalties from the OTL’s share of the recombinant patent.21 Critics said the patent obviously led to underutilization, locking out small start-ups that didn’t receive the grace of VCs. But in terms of dispersing the tech, it’s hard to look askance at the licensing fees and Genentech’s success. At the end of the 1980s, after making many people in Palo Alto very rich, the company was majority-acquired by the Swiss multinational pharmaceuticals conglomerate Roche. By getting the government out of the way, the Bay Area’s capitalists and scientists turned a legally dubious piece of paper into a real company that made drugs that people used. It was their payout for rescuing recombinant DNA from the tragedy of the commons. Boosted by the OTL’s DNA IP, Stanford quickly became the top university in the country in terms of patent income.22 What the public gained or lost in the process is hard to calculate.